The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
about
Copine-III interacts with ErbB2 and promotes tumor cell migrationSTEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumorsA quantitative protein interaction network for the ErbB receptors using protein microarraysExpression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancerOutcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labellingTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerPrognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast CancerOverview of recurrent chromosomal losses in retinoblastoma detected by low coverage next generation sequencingDeciphering Asthma Biomarkers with Protein Profiling TechnologyT cell receptor-like recognition of tumor in vivo by synthetic antibody fragmentPoor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptideStructure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitorDesign, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitorsDNA vaccine for cancer immunotherapyComparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic useClinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare eventPertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancerTranslation in Data Mining to Advance Personalized Medicine for Health Equityt-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer CellsEmbryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls.Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.Revitalizing personalized medicine: respecting biomolecular complexities beyond gene expression.CIG-DB: the database for human or mouse immunoglobulin and T cell receptor genes available for cancer studies.Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.Expression proteomics study to determine metallodrug targets and optimal drug combinations.Transcriptional profiling of ErbB signalling in mammary luminal epithelial cells--interplay of ErbB and IGF1 signalling through IGFBP3 regulation.An RNA interference screen identifies metabolic regulators NR1D1 and PBP as novel survival factors for breast cancer cells with the ERBB2 signature.30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort studyComplexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.Role of axillary surgery in early breast cancer: review of the current evidence.Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma
P2860
Q22001536-1BE1E5F4-783B-49E2-8E93-705FCD5AE8D2Q22010908-FC1E7EE2-FBAD-42C1-9E6A-C720F5F82803Q24293746-E10754B7-B4DA-4582-A165-18AF800B6A67Q24652752-BF0952C8-B3D7-4DB7-814F-28787A9D5E83Q24794988-F99E24A3-0AA2-4313-AF24-3127F474EFE8Q24795614-53BBAA7D-3D4D-4092-959B-2B7E6F29EA02Q25257601-BBE84643-57B3-4ABB-A5E6-1A66F543D42DQ26738987-41B0BB13-FF2B-4456-A8B3-C23F7FA612E7Q26765431-32E1FAB6-F95B-4C37-919B-347BC7539177Q26783095-8EDA50EF-4F14-4390-A78B-7E3956498FCAQ27322455-7C5FC4EC-9628-431A-B334-17B7AA84E0C3Q27620636-336D2573-27D7-41C5-98DD-DA94FF6FAB88Q27639528-10149E99-0378-4C66-B9E3-4E146349E174Q27657423-B9C00041-A030-491B-BA5A-ABD257C06619Q28080919-AC1B3B14-DDF1-4323-9E72-60AFCD8AC44AQ28140514-A3345BDF-AD88-4750-B596-7945B770FA79Q28245213-A868C099-092A-40FE-BC15-EF526222C475Q28246333-305E2F65-14E1-40BA-9232-5E2A1D8518B7Q28315527-D5991ADB-62C6-4B7B-B3C2-142C11B54DCAQ28545954-93C14267-663D-4906-9481-01FC769C37AFQ30403182-ACB2D409-C68B-45B1-BFE1-D0E57352B70CQ30482618-C0655C1F-7749-4D8E-8AC3-70CBD7AC090FQ30544833-20669CA8-4787-4F19-A7F7-6F3C3551DBC2Q30857631-478C4641-A7EC-4F0D-AA58-ACE3CEF95AB2Q30862407-25A30203-097F-4C13-B1A6-21B0889EF16DQ30992830-ACFEB513-3D06-47D9-864F-981AE2B39321Q33570878-2BEE283B-1388-4611-8658-7269E7B91F84Q33642275-509B79EC-EDB7-43DF-A31B-21D20450C239Q33680681-837356D8-13ED-4933-B193-C2318F0BDBBFQ33685955-28AC8DE1-706A-4D0E-A76B-DFF33488CA98Q33692428-0CEE8343-F880-433B-AA04-62F0F57E3461Q33722873-6FD24570-37CB-4CB7-B7F8-8CF05DB95AB1Q33768732-2502C8E6-3ACA-4430-B3B1-F6EE4F10E159Q33801908-D7DCC52B-04F1-41AB-A137-983F1EE4FE4AQ33842800-0271326D-0020-4721-8BD4-94214F6129CFQ33915825-0DD12C90-A648-4EF7-B0DB-C5837D0720A4Q33972653-54DF9E17-A254-4062-AC49-81036A372EDFQ33984756-C84D7CB4-963E-4732-A9C1-C0A916C5FEDFQ34009045-34E2E1ED-1B85-487F-AADD-D65C39FABC08Q34044864-9521EBE3-C89C-4749-84C2-B27445A44A11
P2860
The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@en
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@nl
type
label
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@en
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@nl
prefLabel
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@en
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@nl
P2860
P356
P1433
P1476
The HER-2/neu oncogene in brea ...... actor, and target for therapy.
@en
P2093
P2860
P304
P356
10.1002/STEM.160413
P577
1998-01-01T00:00:00Z